Clinical Trial Update: Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase II study evaluating a 96-hour continuous infusion of paclitaxel followed by cisplatin in patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Taxol (paclitaxel) (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Status: COMPLETED